华森制药：注射用奥美拉唑钠收到药品再注册批准通知书

Core Viewpoint - Huason Pharmaceutical (002907.SZ) has received approval from the Chongqing Municipal Drug Administration for the re-registration of its injectable omeprazole sodium product, indicating a significant regulatory milestone for the company [1] Group 1: Product Approval - The product is indicated for several conditions, including bleeding from peptic ulcers and anastomotic ulcers [1] - It is also approved for acute gastric mucosal damage due to stress and acute gastric mucosal injury caused by non-steroidal anti-inflammatory drugs [1] - The drug serves as an alternative therapy for conditions where oral therapy is not suitable, such as duodenal ulcers, gastric ulcers, gastroesophageal reflux disease, and Zollinger-Ellison syndrome [1]